Published in Mol Neurobiol on December 01, 2003
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci (2011) 1.31
TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuroblastoma cells. J Biol Chem (2004) 1.18
Molecular mechanisms of the conjugated alpha,beta-unsaturated carbonyl derivatives: relevance to neurotoxicity and neurodegenerative diseases. Toxicol Sci (2007) 1.15
Oxidative stress and microglial cells in Parkinson's disease. Mediators Inflamm (2012) 0.96
Validation of nigrostriatal positron emission tomography measures: critical limits. Ann Neurol (2013) 0.95
Modeling Parkinson's disease in primates: The MPTP model. Cold Spring Harb Perspect Med (2012) 0.94
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl) (2007) 0.91
Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease. Parkinsons Dis (2011) 0.89
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. PLoS One (2010) 0.87
Validation of midbrain positron emission tomography measures for nigrostriatal neurons in macaques. Ann Neurol (2013) 0.86
Exercise does not protect against MPTP-induced neurotoxicity in BDNF haploinsufficient mice. PLoS One (2012) 0.82
Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson's disease discerned with microSPECT and quantitative MRI. MAGMA (2010) 0.80
Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's disease. PLoS One (2017) 0.77
Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Biol Chem (2013) 0.77
Oral administration of coenzyme Q₁₀ reduces MPTP-induced loss of dopaminergic nerve terminals in the striatum in mice. Neurol Sci (2011) 0.76
Protective effects of a polysaccharide from Spirulina platensis on dopaminergic neurons in an MPTP-induced Parkinson's disease model in C57BL/6J mice. Neural Regen Res (2015) 0.75
Dissecting the role of Engrailed in adult dopaminergic neurons - Insights into Parkinson disease pathogenesis. FEBS Lett (2015) 0.75
Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms. Front Neuroanat (2017) 0.75
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci (2003) 2.41
Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. Biol Psychiatry (2008) 2.35
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol (2014) 2.33
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 2.28
Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov (2006) 2.23
Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain (2005) 2.19
Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A (2012) 2.16
Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol (2010) 1.80
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol (2009) 1.70
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 1.65
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging (2008) 1.58
Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model. Mov Disord (2012) 1.51
DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization. J Nucl Med (2008) 1.49
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia. J Neurosci (2012) 1.48
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor. J Neurosci (2012) 1.43
Deep brain stimulation for Parkinson's disease: potential risk of tissue damage associated with external stimulation. Ann Neurol (2004) 1.42
Coordinated reset has sustained aftereffects in Parkinsonian monkeys. Ann Neurol (2012) 1.42
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. J Neurosci (2007) 1.35
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci (2004) 1.30
Lysosomal impairment in Parkinson's disease. Mov Disord (2013) 1.27
Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism. Eur J Neurosci (2007) 1.27
Shaping of motor responses by incentive values through the basal ganglia. J Neurosci (2007) 1.24
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Sci Transl Med (2010) 1.23
Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? Prog Neurobiol (2008) 1.19
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol (2002) 1.17
Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J Neurosci (2003) 1.16
Dynamic changes in the cortex-basal ganglia network after dopamine depletion in the rat. J Neurophysiol (2008) 1.15
Regional characterization of energy metabolism in the brain of normal and MPTP-intoxicated mice using new markers of glucose and phosphate transport. J Biomed Sci (2010) 1.14
The nigrostriatal pathway in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol (2009) 1.13
Microarray analysis of nonhuman primates: validation of experimental models in neurological disorders. FASEB J (2003) 1.13
Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord (2005) 1.13
Maternal exposure to LPS induces hypomyelination in the internal capsule and programmed cell death in the deep gray matter in newborn rats. Pediatr Res (2006) 1.11
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J Neurosci (2009) 1.09
Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One (2010) 1.08
Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat. J Neurochem (2004) 1.08
Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One (2012) 1.07
Antagonizing L-type Ca2+ channel reduces development of abnormal involuntary movement in the rat model of L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry (2008) 1.07
The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. Am J Clin Nutr (2002) 1.07
Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate. PLoS One (2010) 1.07
Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. J Neurosci (2006) 1.07
Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nucl Med Biol (2011) 1.06
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis (2007) 1.06
Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int (2008) 1.05
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A (2010) 1.05
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis (2010) 1.04
Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radic Biol Med (2005) 1.04
Fetal exposure to teratogens: evidence of genes involved in autism. Neurosci Biobehav Rev (2010) 1.02
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci (2008) 1.02
PET radioligands for the vesicular acetylcholine transporter (VAChT). Curr Top Med Chem (2010) 1.01
Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry (2007) 1.01
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci (2005) 1.01
5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis (2006) 1.00
Endogenous morphine-like compound immunoreactivity increases in parkinsonism. Brain (2011) 1.00
Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry (2009) 1.00
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci (2005) 1.00
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol Psychiatry (2006) 1.00
Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation? Behav Brain Res (2012) 1.00
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis (2006) 0.99
PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest (2012) 0.98
Traditional Chinese medicine for Parkinson's disease: a review of Chinese literature. Behav Pharmacol (2006) 0.97
Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage. J Lipid Res (2002) 0.97
[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging (2003) 0.96
Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett (2009) 0.96
Protein aggregation in the aging retina. J Neuropathol Exp Neurol (2011) 0.96
Dopamine receptors and L-dopa-induced dyskinesia. Parkinsonism Relat Disord (2009) 0.96
PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging (2012) 0.94
Rise and fall of minocycline in neuroprotection: need to promote publication of negative results. Exp Neurol (2004) 0.94
Modeling Parkinson's disease in primates: The MPTP model. Cold Spring Harb Perspect Med (2012) 0.94
Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET. Bioorg Med Chem (2005) 0.93
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp Neurol (2004) 0.93
Misrepresentation of neuroscience data might give rise to misleading conclusions in the media: the case of attention deficit hyperactivity disorder. PLoS One (2011) 0.92
Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol Aging (2011) 0.92
Ontogeny of the dopamine and serotonin transporters in the rat brain: an autoradiographic study. Neurosci Lett (2004) 0.92
Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. Bioorg Med Chem (2005) 0.91
Molecular mechanisms of l-DOPA-induced dyskinesia. Int Rev Neurobiol (2011) 0.91
Noradrenergic modulation of subthalamic nucleus activity: behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats. J Neurosci (2007) 0.90